Shock Wave Therapy for Sural Myofascial Pain Syndrome Associated With Plantar Fasciitis: a Pilot Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tendinopathy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Enrollment
- 55
- Primary Endpoint
- Change in FFI-foot function index
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The aim of this randomized controlled study in to investigate if a shock wave treatment extended to the gastrocnemius-soleus trigger points (TrP) is more effective than a standard treatment exclusively targeted at the plantar fascia in a population affected by unilateral plantar fasciitis with concomitant sural myofascial pain syndrome.
Investigators
Ettore Carlis
Physician specialised in physical medicine and rehabilitation
Fondazione IRCCS Policlinico San Matteo di Pavia
Eligibility Criteria
Inclusion Criteria
- •Adult age (18 to 75 years) and written informed consent;
- •Unilateral heel pain of four weeks or longer duration;
- •Pain to digital pressure in the insertional area of the plantar fascia at the calcaneum;
- •Sonographic examination showing a plantar fascia thickness greater than 3.8mm (see procedures for details);
- •Concomitant presence of a sural myofascial pain syndrome (SMPS), diagnosed on the basis of the finding, at the physical examination, of trigger points of the gastrocnemius-soleus muscle complex, according to Travel and Simons' original description.
Exclusion Criteria
- •No corticosteroid injections or other physical therapies since the onset of the current pain episode (except pharmacological pain treatments and foot orthoses);
- •No general contraindication to shock wave therapy (pregnancy, bleeding disorders or anticoagulant drug usage, cancer in the focal area);
- •No clinical signs of lumbar radiculopathy at physical examination;
- •No ankle osteoarthritis, diagnosed on the basis of clinical and radiographic findings;
- •No previous fractures or surgery in the affected ankle and foot;
- •No rheumatologic diseases, no plantar fibromatosis
Outcomes
Primary Outcomes
Change in FFI-foot function index
Time Frame: FFI was administered at baseline, at two months time point and at three months time point
Foot Function Index is self-administered questionnaire designed to measure foot performances in relation to symptoms. Foot Function Index is structured in two sections of nine items each, investigating foot pain (FFI-A) and function (FFI-B) respectively. The total score of each section ranges from zero (no pain/no functional limitation) to 100 (intolerable pain/complete inability). The two scores were separately analysed.
Secondary Outcomes
- Change in PPT-pressure pain threshold(PPT was recorded at baseline, at two months time point and at three months time point)